Truffle Capital

Founded in 2001, Truffle Capital is an independent European private equity firm investing in spin-offs in the Energy, Information Technologies and Life Sciences sectors.Truffle Capital invests mainly in European companies that are active in both Europe and high-growth countries in North Africa and the Middle East, as well as in India and Brazil. Truffle Capital concentrates on the following Information Technologies areas: mobile content and connectivity, Internet, technical software, IT security, and VOIP. Truffle Capital’s Life Sciences team focuses on three areas: therapeutic drugs and vaccines, medical devices, and breakthrough technologies.
BA

Bozena Adamczyk

Directeur Investissement, Fintech, Expert Finance

Mark Bivens

Operating Partner, Fintech, Expert Saas

JB

Joseph Boudara

Investor Relations

AC

Alain Chevallier

Senior Partner, Biomedtech

CC

Claire Corot

Senior Partner, Biomedtech

Daniele Genovesi

Partner, Fintech, Expert Intelligence Artificielle

Sneha Hiremath

Head of Investor Relations

Gaetano Insalaco

CFO and Partner

Olga Koulechova

Partner and Head of Investor Relations and Marketing

PK

Patrick Kron

President

ML

Maud Lazare

Directrice Relations Investisseurs, Partner

EL

Emilie Lhopitallier

Secretaire Generale, Partner

Patrick Lord

Senior Partner, Fintech, Specialiste De La Blockchain

Antoine Pau

Senior Partner, Biomedtech

Philippe Pouletty

Co-Fondateur, Directeur General

Bernard-Louis Roques

Co-Fondateur, Directeur General

ES

Eric Sejor

Partner, Biomedtech

51 past transactions

Acasi SAS

Seed Round in 2021
Acasi SAS develops accounting management software for freelancers. It offers online quotation and invoicing, managing VAT, automatic transmission of your expenses, cash in real time, and automatic accounting management. The company was incorporated in 2017 and is based in Paris, France.

MoneyTrack

Pre Seed Round in 2017
MONEYTRACK SAS provides a blockchain-based directed payment platform for insurance reimbursement services. Its platform validates payment contracts between financiers, issuers, beneficiaries, merchants, and payment institutions in the directed payment chain. The company was founded in 2018 and is based in Paris, France.

MoneyTrack

Pre Seed Round in 2017
MONEYTRACK SAS provides a blockchain-based directed payment platform for insurance reimbursement services. Its platform validates payment contracts between financiers, issuers, beneficiaries, merchants, and payment institutions in the directed payment chain. The company was founded in 2018 and is based in Paris, France.

Pharnext SA

Series A in 2010
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

RF-iT Solutions

Series A in 2006
RF-iT Solutions GmbH provides radio frequency identification (RFID) software solutions and services. It develops and markets You-R® OPEN, an auto-ID software and RFID operating environment, which serves as a platform for system integrators, software manufacturers, and operators, as well as supports RFID infrastructure ranging from smart labels to readers, barcode scanners, label printers, and I/O devices. The company also provides RFID middleware; You-R Smart Fashion, a textile and apparel supply chain solution; You-R® DOCUTRACER, a Web-based application that stores data in a SQL-database for patent lawyers and hospitals; You-R® PHARMA, a solution for local packaging lines to capture item serial numbers, as well as the hierarchy of case/pallet serial numbers in pharmaceutical companies; You-R® RETAIL, an inventory solution for retailers; You-R® SECURE, a solution for manufacturer brand protection; and You-R® VIRTUAL TUNNEL, a solution the enables the allocation of single units to their packing units. In addition, it offers business case analysis, feasibility studies, testing, and technology consulting services. The company serves fashion, automotive, industrial manufacturing, pharmaceutical, retail, consumer packaged goods, logistics, asset management, and healthcare industries. RF-iT Solutions GmbH was founded in 2005 and is based in Graz, Austria. It has locations in Germany, France, and the United Kingdom.

AS Group

Funding Round in 2005
AS Group is a Parisian company and a spin-off of Deloitte, was a corporate performance software vendor.

Cytomics Pharmaceuticals

Series B in 2006
Cytomics Systems is a French private company that offers bio-pharmacology services. The company uses Yeast Micro-Lab technology, a protenomics tool, which enables to follow in-vitro deterioration of proteins. Cytomics Systems's research and development focuses on fungicidal infections, inflammatory illnesses, and cancers. Cytomics Systems, S.A was founded in 2000 and is based in Gif-sur-Yvette, France.

Cachet OÜ

Series A in 2022
Cachet is a "trustee" data layer between the sharing economy platforms and insurance providers. We aggregate and enrich cross-market data about how much service providers are providing service on various competing platforms and via that enable insurance companies to sell more personalised coverage. We have started with the ride-hailing/mobility sector since it has the highest number of participants.

MoneyTrack

Series A in 2021
MONEYTRACK SAS provides a blockchain-based directed payment platform for insurance reimbursement services. Its platform validates payment contracts between financiers, issuers, beneficiaries, merchants, and payment institutions in the directed payment chain. The company was founded in 2018 and is based in Paris, France.

Smile&Pay SAS

Venture Round in 2018
Smile & Pay offers electronic payment terminals that enable small and medium merchants to accept payments from a large customer base with smartphones for no fixed fee. The company’s products include PocketSmile, a mobile-sized terminal that accepts all credit cards; and MaxiSmile, a terminal that features a printer and mobile GPRS facilities. With Smile & Pay’s payment solutions, individuals can also track their receipts in real time through their computers or phones.

IPaidThat

Seed Round in 2019
IPaidThat automatically imports the invoices you receive, and compares them with your bank transactions, to make sure you do not forget anything.

Monisnap SAS

Series A in 2021
Monisnap is the new alternative to sent money abroad. Send money to your relatives, friends or business partners in seconds, and enjoy the fairest fees and smartest experience on our platform! Monisnap was founded in 2017 by former employees from Google and Groupon, finally bringing to life the long-awaited disruption in the traditional European remittance market, which suffers from poor customer satisfaction, high fees and dull products. Monisnap is a France based start-up, authorized to work as a banking intermediary by French Financial Authority ORIAS (n°17006312).

SP3H

Venture Round in 2012
SP3H's values are in tune with the environmental and energetic stakes of the 21st century. For this reason, their company innovates in ground-breaking technology, which aims to reduce carbon dioxide levels and fuel consumption.

Zaion SAS

Series A in 2021
Zaion SAS develops integrated oral and written conversation solutions (callbot/voicebot). Its solutions allow to handle calls in natural language and text-based conversations in natural language; supervise customer interactions; and facilitate insightful reporting, and IS and CRM system integration. The company was founded in 2017 and is based in Paris, France.

RollingFunds

Venture Round in 2022
RollingFunds offers short term financing to small and medium enterprises. The company was founded in 2018 and is headquartered in Paris, France.

Biokinesis

Funding Round in 2011
Biokinesis is a biotechnology company developing new treatments for cancer by targeting a specific kinesin found in several cancers.

Symetis SA

Series B in 2009
Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Actility

Seed Round in 2010
Actility is an industry leader in Low Power Wide Area Networks (LPWAN). ThingPark by Actility offers a carrier-grade IoT platform, with a growing ecosystem of partners; low-power, long-range wireless networks for sensors and devices; an operating system and middleware that enables web applications to connect seamlessly with data from different sensors; and a B2B e-commerce market featuring tested and approved IoT device, connectivity, and application partners. Actility is a founding member of the LoRa Alliance™.

Monisnap SAS

Seed Round in 2019
Monisnap is the new alternative to sent money abroad. Send money to your relatives, friends or business partners in seconds, and enjoy the fairest fees and smartest experience on our platform! Monisnap was founded in 2017 by former employees from Google and Groupon, finally bringing to life the long-awaited disruption in the traditional European remittance market, which suffers from poor customer satisfaction, high fees and dull products. Monisnap is a France based start-up, authorized to work as a banking intermediary by French Financial Authority ORIAS (n°17006312).

CoolGames

Funding Round in 2012
Using 100% HTML5 technology, CoolGames has published hundreds of top-quality casual games including high-profile IPs such as Angry Birds, Tetris®, Snake, and Battleship since 2009. Click-and-play from the cloud with no downloads required, you can enjoy our everyday growing game portfolio anytime and anywhere!

IPaidThat

Venture Round in 2021
IPaidThat automatically imports the invoices you receive, and compares them with your bank transactions, to make sure you do not forget anything.

Equitime

Funding Round in 2004
EquiTime provides organizations with Workforce Management Solutions which allow them to build, follow, count and analyse employee schedules while respecting the specificities of each profession. EquiTime renews the traditional concepts of time and activity management by adding the forecasting dimension to that of the actual work already done, which represents a source of increased productivity, and an improvement in the relations between company employees and customers.

Immune Targeting Systems

Series A in 2007
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Geocorail

Venture Round in 2015
Géocorail développe et commercialise un produit innovant faisant travailler la mer à la protection du littoral : le Géocorail®. Ce procédé électrochimique breveté innovant consiste à créer une roche artificielle permettant de protéger les ouvrages marins et de lutter contre l’érosion du littoral.
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

PeopleCube

Venture Round in 2007
As of November 9, 2005, PeopleCube (UK) was acquired by PeopleCube, Inc. (formerly known as Meeting Maker, Inc.). PeopleCube provides intelligent on-demand workplace management solutions that help customers cut real estate, meeting services, travel, and energy costs based on actual workspace usage. Through its corporate headquarters in Framingham, Massachusetts, and offices throughout the world, PeopleCube supports 7,500 customers in small, medium, and large enterprises. PeopleCube helps businesses cut real estate, meeting services, travel and energy costs based on actual workspace usage. The UK predecessor, formerly known as The Internet Applications Group (UK), Ltd., was founded in 1995 and is based in Twickenham, the United Kingdom with an additional office in the Netherlands.

Pharnext SA

Venture Round in 2012
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

CARMAT

Funding Round in 2008
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, pulsatile, and implantable systems, as well as power supply systems. The company was founded in 2008 and is based in Vélizy-Villacoublay, France.

Deinove SA

Funding Round in 2006
Deinove SA is a France-based company active in the renewable fuels sector. It specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value.

Pharnext SA

Series B in 2011
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

Theradiag SA

Series C in 2005
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

Actility

Series C in 2015
Actility is an industry leader in Low Power Wide Area Networks (LPWAN). ThingPark by Actility offers a carrier-grade IoT platform, with a growing ecosystem of partners; low-power, long-range wireless networks for sensors and devices; an operating system and middleware that enables web applications to connect seamlessly with data from different sensors; and a B2B e-commerce market featuring tested and approved IoT device, connectivity, and application partners. Actility is a founding member of the LoRa Alliance™.

MoneyTrack

Funding Round in 2017
MONEYTRACK SAS provides a blockchain-based directed payment platform for insurance reimbursement services. Its platform validates payment contracts between financiers, issuers, beneficiaries, merchants, and payment institutions in the directed payment chain. The company was founded in 2018 and is based in Paris, France.

CoolGames

Series A in 2013
Using 100% HTML5 technology, CoolGames has published hundreds of top-quality casual games including high-profile IPs such as Angry Birds, Tetris®, Snake, and Battleship since 2009. Click-and-play from the cloud with no downloads required, you can enjoy our everyday growing game portfolio anytime and anywhere!

RollingFunds

Series A in 2019
RollingFunds offers short term financing to small and medium enterprises. The company was founded in 2018 and is headquartered in Paris, France.

Altimmune

Post in 2015
Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies. Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors.

Particeep

Venture Round in 2021
Particeep is a fintech that provides banks, asset management firms, insurances and their distributors an API technology, enabling them to distribute their financial products and services online. The company offers, in addition to its API integrating ready-to-use banking and insurance micro-services, white-label platforms to industrialise the online distribution of banking, insurance and investment products. Particeep is a young innovative firm, winner of the 2017 and 2018 Banque et Innovation Fintech and Open Banking awards, elected Future Fintech European Star 2016 (ICT Awards 2016) and selected by Challenges in the 2016 ranking of 100 startups to invest in

WeGroup NV

Series A in 2020
WeGroup helps insurance providers to make a better connection with their growing group of digital customers. Thanks to applying data analytics and machine learning algorithms, WeGroup’s 24/7 digital assistant ‘Louise’ helps insurance intermediaries, service providers and carriers to have a better understanding of their clients need and risk profiles, as well as automating several processes such as claims handling and compliancy.

Carbios

Funding Round in 2012
Carbios SAS, a green chemistry company, develops industrial bioprocesses for the biodegradation and bio recycling of polymers. The company produces enzymated pellets for use in the production of biosourced and biodegradable plastics. It also recycles plastic waste into plastic materials; and produces polylactic acid. Carbios SAS has a development agreement with Novozymes to produce enzyme for recycling of PET-plastics and fibers. The company was founded in 2011 and is headquartered in Saint-Beauzire, France.

Momac B.V.

Series B in 2013
Momac simplifies customer engagement for leading communication service providers. By bridging the technology gap between internal data systems, service offerings, content and on-device user interfaces, Momac allows CSPs to reduce costs, increase revenue and rapidly bring solutions to market. The mvolve platform drives mobile internet and app solutions for leading CSOs and operator groups around the world, including Orange Group, Vodafone, Telefonica, Three, KPN, T-Mobile, and more. Operating in 27 countries, Momac has offices in the US, UK, the Netherlands and France.

Theradiag SA

Series B in 2003
Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

OSEAD Maroc Mining

Private Equity Round in 2007
OSEAD Maroc Mining operates as a metal and mining platform. OSEAD is a holding company specialising in the prospecting, exploration and mining of mineral deposits. OSEAD’s main asset is Compagnie Minière de Touissit the second largest private mining operator in Morocco, which mines primarily lead and silver with some zinc.
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

Theraclion

Post in 2015
Theraclion Société anonyme develops, manufactures, and markets therapeutic ultrasound equipment. It offers an echotherapy solution that combines high-intensity focused ultrasound therapy with ultrasound as a system for locating target areas for the non-invasive treatment of benign tumours. The company also offers Echopulse for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners; and SONOVEIN, an echotherapy solution using therapeutic ultrasound for the treatment of varicose veins. It operates in approximately 20 countries worldwide. The company was founded in 2004 and is based in Malakoff, France.

Immune Targeting Systems

Series A in 2010
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Eco-Carbone

Funding Round in 2008
Eco-Carbone provides consulting and project development services in the area of climate change mitigation.

Smile&Pay SAS

Series B in 2021
Smile & Pay offers electronic payment terminals that enable small and medium merchants to accept payments from a large customer base with smartphones for no fixed fee. The company’s products include PocketSmile, a mobile-sized terminal that accepts all credit cards; and MaxiSmile, a terminal that features a printer and mobile GPRS facilities. With Smile & Pay’s payment solutions, individuals can also track their receipts in real time through their computers or phones.

Neovacs

Venture Round in 2007
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

SP3H

Venture Round in 2014
SP3H's values are in tune with the environmental and energetic stakes of the 21st century. For this reason, their company innovates in ground-breaking technology, which aims to reduce carbon dioxide levels and fuel consumption.

Utel

Venture Round in 2011
Utel SAS operates as a mobile application creator for social networking and collaborative services. The company provides Allokang, a Web platform that allows clients to buy or sell skills, talents, and expertise in the fields of legal, financial, academic support, IT, mental health issues, well-being, personal development, entertainment, astrology, clairvoyance, etc. It also offers Backstage SMS, a solution to start a game, a vote, etc.; a Web interface that allows animators to consult messages received from listeners; a photo and video function that allows listeners to send photos and video contents, while allowing animators to make related activities; and a solution that allows animators to monetize the traffic on community pages allowing listeners to participate in surcharged games with a click. The company was incorporated in 2000 and is based in Paris, France.